Welcome to our dedicated page for VIVO news (Ticker: VIVO), a resource for investors and traders seeking the latest updates and insights on VIVO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VIVO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VIVO's position in the market.
Meridian Bioscience (NASDAQ: VIVO) announced the launch of two innovative Air-Dryable™ qPCR Mixes, enhancing direct detection of DNA or RNA from urine samples. These mixes address the inhibition challenges associated with crude urine samples, allowing for faster and more sensitive molecular assays without the need for tedious purification. This innovative technology simplifies assay setup, making it cost-effective and suitable for point-of-care applications. Meridian's commitment to innovation positions it to deliver superior diagnostic solutions, improving patient compliance and satisfaction.
Meridian Bioscience (NASDAQ: VIVO) will announce its fourth quarter and full year 2021 financial results on November 12, 2021. The event will feature a conference call at 10:00 a.m. Eastern Time led by CEO Jack Kenny and CFO Bryan Baldasare. A live webcast will be available for investors, alongside a telephone option for participants. Additionally, a recorded version will be accessible for one year post-event. Meridian specializes in diagnostic products across various sectors, providing essential solutions globally.
Meridian Bioscience (NASDAQ: VIVO) launched its new Air-Dryable™ Direct RNA/DNA qPCR Blood Mix, designed for rapid and sensitive detection of viral and bacterial infections directly from blood samples. This innovative product simplifies the development of molecular diagnostics by eliminating the need for costly DNA/RNA purification. Compatible with air-drying, it replaces traditional lyophilization methods, reducing manufacturing costs and enhancing workflow efficiency. The technology supports applications in cancer management and forensic analyses, emphasizing Meridian's commitment to accelerating diagnostic solutions.
Meridian Bioscience recently launched two innovative Air-Dryable™ Master Mixes: the Air-Dryable™ Direct DNA qPCR Stool and Air-Dryable™ Direct RNA/DNA qPCR Stool Mixes. These products facilitate room-temperature stable molecular diagnostics from crude stool samples, eliminating the need for complex purification steps. This technology enhances assay speed and sensitivity, making it valuable for applications like gastrointestinal disease diagnosis. Meridian aims to simplify the development of diagnostic assays and is committed to accelerating solutions in the diagnostic industry. Shares are traded on NASDAQ under the symbol VIVO.
Meridian Bioscience announced the launch of its new Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva Mixes, enabling room-temperature stable molecular assays from saliva and sputum samples. These products address challenges in diagnostics due to PCR inhibitors in saliva, allowing for direct diagnosis without extensive sample processing. Dr. Lourdes Weltzien highlighted benefits such as reduced healthcare worker exposure and cost savings for manufacturers. Meridian aims to simplify diagnostic development and improve assay performance.
Meridian Bioscience (NASDAQ: VIVO) announced an expansion of the voluntary recall of its LeadCare Test Kits for lead detection in blood due to control test failures. The recall, initiated in May 2021, affects various lot numbers and underscores the risk of underestimating blood lead levels. The company recommends discontinuing the use of these kits and evaluating patient test results with alternative methods. The U.S. FDA has been notified of the situation, and product distribution has been paused until further notice.
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced its participation in the H. C. Wainwright 23rd Annual Global Investment Conference. CEO Jack Kenny's pre-recorded presentation will be accessible starting September 13, 2021, at 7:00 am ET.
The presentation can be viewed for 90 days on the Company’s Investor Relations website. Meridian, a life science company, develops and distributes innovative diagnostic products, serving clients in over 70 countries. For details on the conference, visit the official website.
Meridian Bioscience reported Q3 2021 net revenues of $63.5 million, a 25% decline from Q3 2020 but a 31% increase from Q3 2019. The diagnostics segment grew 44% year-over-year to $31.2 million, while the life science segment decreased by 49% to $32.3 million. Operating income fell 55% to $15.7 million, though adjusted operating income was $12.9 million with a margin of 20%. The company reaffirmed its 2021 revenue guidance of $308 million to $314 million.
CINCINNATI, Aug. 2, 2021 - Meridian Bioscience announced the acquisition of the North American BreathTek® business from Otsuka America Pharmaceutical, effective July 31, 2021. This strategic move aims to enhance Meridian's diagnostic testing solutions and strengthen its market position. Financial impacts related to the acquisition will be discussed in the upcoming quarterly earnings call on August 6, 2021. Meridian is a global leader in diagnostic solutions, trading under the NASDAQ symbol VIVO.
Meridian Bioscience announced the acquisition of North America's BreathTek® business from Otsuka America Pharmaceutical for $20 million in cash, expected to close in the fiscal fourth quarter. This acquisition will provide Meridian with customer relationships for the urea breath test used to detect Helicobacter pylori, adding over $20 million to annual revenue. The CEO stated that this move leverages pandemic-generated cash to enhance Meridian's diagnostics segment, contributing to immediate earnings and cash growth.
FAQ
What is the market cap of VIVO (VIVO)?
